GLPBio

RET

Read More about this category

RET (REarranged during Transfection) is a receptor protein tyrosine kinase, which activates multiple signal transduction pathways. RET protein is composed of three domains: an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. The RET receptor tyrosine kinase (RTK) regulates key aspects of cellular proliferation and survival by regulating the activity of the mitogen- activated protein kinase (MAPK) and PI3K/Akt signaling pathways. RET also interacts directly with other kinases such as the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) and the focal adhesion kinase (FAK). Furthermore, BRAF and p38MAPK are downstream targets of RET. Kinase inhibitors that simultaneously inhibit RET and its downstream targets.

RET tyrosine kinase receptor presents an attractive therapeutic target for the treatment of certain cancer subsets. Deregulated RET activity has been identified as a causative factor in the development, progression and response to therapy of thyroid carcinoma. Elevated RET expression has been associated with the development of endocrine resistance in human breast cancer.

Products Related to RET(32)

  • GC65354 structure
    GC65354Enbezotinib
    CAS: 2359649-81-1
    Purity: >99.00%

    Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer.

  • GC67917 structure
    GC67917RET-IN-7
    CAS: 2763386-05-4
    Purity: >98%
  • GC68396 structure
    GC68396Vepafestinib
    CAS: 2129515-96-2
    Purity: >98.00%
  • GC68623 structure
    GC68623AD57
    CAS: 1093380-42-7
    Purity: >98.00%

    AD57 is a type of orally active multi-kinase inhibitor that inhibits the activity of RET, BRAF, S6K and Src, but has significantly reduced activity against mTOR.

  • GC68812 structure
    GC68812BT44
    CAS: 924759-42-2
    Purity: >99.00%

    BT44 is a selective RET activator. It can penetrate the blood-brain barrier and can be used for research on neurodegenerative diseases and diabetes.

  • GC73196 structure
    GC73196RET-IN-21
    CAS: 2414373-42-3
    Purity: >97.00%

    RET-IN-21 is an inhibitor of receptor tyrosine kinase (RET), with the IC50 of 4.4 μM, that has antitumor activity.

  • GC79484 structure
    GC79484APS03118
    CAS: 2598870-24-5
    Purity: >98.50%

    APS03118 is an orally active, potent and selective rearranged during transfection ( RET ) inhibitor.

  • GC81325 structure
    GC81325VEGFR2-IN-84
    CAS: 861877-12-5
    Purity: >98%

    VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold.